** Shares of drug developer BioRestorative Therapies
rise ~7% to $1.75 premarket
** Co reports preliminary data from ongoing mid-stage study testing BRTX-100, its lead cell therapy candidate to treat chronic lumbar disc disease
** Lumbar disc disease, also known as degenerative disc disease, occurs when spinal discs in lower back area begins to wear away
** No serious side-effects were reported in 10 safety run-in subjects, BRTX says
** Co says blinded data from 10 trial participants showed BRTX-100 helped improve pain and function
** Up to last close, stock down ~6% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。